Moderna Therapeutics

Moderna Therapeutics

Moderna Therapeutics is a biotechnology company that researches and develops protein therapies based on novel messenger RNA (mRNA) technology. The company’s technology uses mRNA made of nucleotide analogs to trigger the body’s natural processes to produce proteins inside the human cell. Wikipedia

Moderna Therapeutics

Moderna Therapeutics is a biotechnology company that researches and develops protein therapies based on novel messenger RNA (mRNA) technology. The company’s technology uses mRNA made of nucleotide analogs to trigger the body’s natural processes to produce proteins inside the human cell. Wikipedia

  • Nov 1 at 1:36 PM
    Moderna and AstraZeneca will advance a new development candidate AZD7970, a novel mRNA therapeutic encoding for Relaxin, to address the serious unmet need for heart failure treatments.
  • Oct 18 at 0:10 AM
    So proud of the progress our team continues to make on behalf of patients. Weve now filed an IND for our 10th mRNA medicine in less than two years!
  • Sep 14 at 7:53 PM
    As part of our corporate update today, we announced that our partner, AstraZeneca, successfully completed a Phase 1 study of mRNA AZD-8601, encoding for VEGF1. The study met both its primary and secondary endpoints. AstraZeneca has filed a CTA for a Phase 2a study in heart failure patients undergoing CABG surgery.
  • Sep 14 at 11:06 AM
    Our updated development pipeline includes 16 mRNA medicines. We have Phase 1 studies underway for 7 programs, with 9 programs advancing toward the clinic. We've made major steps forward advancing mRNA therapeutics for cardiovascular disease, immune-oncology and rare liver diseases.

Nov 1, 1:36 PM

Moderna and AstraZeneca will advance a new development candidate AZD7970, a novel mRNA therapeutic encoding for Relaxin, to address the serious unmet need for heart failure treatments.

Oct 18, 0:10 AM

So proud of the progress our team continues to make on behalf of patients. Weve now filed an IND for our 10th mRNA medicine in less than two years!

Sep 14, 7:53 PM

As part of our corporate update today, we announced that our partner, AstraZeneca, successfully completed a Phase 1 study of mRNA AZD-8601, encoding for VEGF1. The study met both its primary and secondary endpoints. AstraZeneca has filed a CTA for a Phase 2a study in heart failure patients undergoing CABG surgery.

Sep 14, 11:06 AM

Our updated development pipeline includes 16 mRNA medicines. We have Phase 1 studies underway for 7 programs, with 9 programs advancing toward the clinic. We've made major steps forward advancing mRNA therapeutics for cardiovascular disease, immune-oncology and rare liver diseases.

30 jobs at Moderna Therapeutics

Jobs in